Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 30-36

  Murakami, Toshi ^a   Takigawa, Nagio ^b   Ninomiya, Takashi ^a   Ochi, Nobuaki ^b   Yasugi, Masaaki ^a   Honda, Yoshihiro ^a   Kubo, Toshio ^a   Ichihara, Eiki ^a   Hotta, Katsuyuki ^a   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^c  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

EGFR; JAK2; Lung cancer; Oncogene addiction; STAT3; Transgenic mice

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 1; JANUS KINASE 2 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL LINE; CONTROLLED STUDY; FEMALE; GROWTH INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KAPLAN MEIER METHOD; LUNG CANCER; MOUSE; MTT ASSAY; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; TRANSGENIC MOUSE; TUMOR REGRESSION; TUMOR XENOGRAFT;

EGFR; JAK2; LUNG CANCER; ONCOGENE ADDICTION; STAT3; TRANSGENIC MICE;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; EXONS; FEMALE; HUMANS; JANUS KINASE 2; LUNG NEOPLASMS; MICE; MICE, NUDE; MICE, TRANSGENIC; MUTATION; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PYRAZOLES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84891747089     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.10.011     Document Type: Article

References (21)

1. Jemal A., Thun M.J., Ries L.A., Howe H.L., Weir H.K., Center M.M., et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008, 100:1672-1694.
2. William W.N., Lin H.Y., Lee J.J., Lippman S.M., Roth J.A., Kim E.S. Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009, 136:701-709.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305:1163-1167.
5. Haura E.B., Zheng Z., Song L., Cantor A., Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005, 11:8288-8294.
6. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
7. Schindler C., Darnell J.E. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995, 64:621-651.
8. Johnston J.A., Kawamura M., Kirken R.A., Chen Y.Q., Blake T.B., Shibuya K., et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994, 370:151-153.
9. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., et al. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
10. Xin H., Herrmann A., Reckamp K., Zhang W., Pal S., Hedvat M., et al. Anti-angiogenic and anti-metastatic activity of JAK inhibitor AZD1480. Cancer Res 2011, 71:6601-6610.
11. Ohashi K., Rai K., Fujiwara Y., Osawa M., Hirano S., Takata K., et al. Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter. Cancer Sci 2008, 99:1747-1753.
12. Takata S., Takigawa N., Segawa Y., Kubo T., Ohashi K., Kozuki T., et al. STAT3 expression in activating EGFR-driven adenocarcinoma of the lung. Lung Cancer 2012, 75:24-29.
13. Ogino A., Kitao H., Hirano S., Uchida A., Ishiai M., Kozuki T., et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res 2007, 67:7807-7814.
14. Ichihara E., Ohashi K., Takigawa N., Osawa M., Ogino A., Tanimoto M., et al. Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Cancer Res 2009, 69:5091-5098.
15. Harada D., Takigawa N., Ochi N., Ninomiya T., Yasugi M., Kubo T., et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci 2012, 103:1795-1802.
16. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
17. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007, 117:3846-3856.
18. Song L., Rawal B., Nemeth J.A., Haura E.B. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. Mol Cancer Ther 2011, 10:481-494.
19. Yu H., Jove R. The STATs of cancer - new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
20. Ninomiya T., Takigawa N., Ichihara E., Ochi N., Murakami T., Honda Y., et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 2013, 12:589-597.
21. Ohashi K., Takigawa N., Osawa M., Ichihara E., Takeda H., Kubo T., et al. Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice. Cancer Res 2009, 69:7088-7095.